الفهرس 
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 141 |  |  |
| | | from | 141 | | |
Abstract
This randomized, prospective and controlled study comprised 50 of low immunologic risk patients who received their living renal allograft in the period between July 2012 to June 2014 at Mansoura urology and nephrology center, dialysis and renal transplantation unit. All of recruited patients were regularly followed-up for 12 months post-transplantation in our center. We randomized all patients with normal histological findings into two groups: group 1: continued to receiving tacrolimus and mycophenolate mofetil. group 2: shifted from tacrolimus to sirolimus and continued on mycophenolate mofetil. Results: After one year of follow up, there was no statistically significant difference between both groups as regard serum creatinine and creatinine clearance. At one year biopsy we found normal histology for most of the patients. Only one case of subclinical rejection and acute cellular rejection grade 1A were detected in sirolimus group.